Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy: From Cell Culture to Clinical Trial

被引：0
|
作者：
Ashar, Jignya [1 ]
Partridge, Terence [2 ]
Lu, Qi L. [1 ]
机构：
[1] Carolinas Med Ctr, MocColl Lockwood Lab Muscular Dystrophy Res, Charlotte, NC 28203 USA
[2] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.800
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
721
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [1] Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy
    Kinali, M.
    Arechavala-Omeza, V.
    Feng, L.
    Glover, A.
    Guglieri, M.
    Jungbluth, H.
    Roper, H.
    Quinlivan, R. M.
    Hunt, D.
    Marizur, A. M.
    Henderson, A.
    Gosalakkal, J.
    Hollingsworth, K.
    Allsop, J.
    Mercuri, E.
    Morgan, J.
    Sewry, C.
    Straub, V.
    Bushby, K.
    Rutherford, M.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 773 - 773
  • [2] Antisense Oligonucleotide for Treating Duchenne Muscular Dystrophy
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 12 - 12
  • [3] Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
    Aoki, Yoshitsugu
    Yokota, Toshifumi
    Wood, Matthew J. A.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [4] Optimization of preclinical antisense oligonucleotide development for Duchenne muscular dystrophy
    Kolfschoten, I. G. M.
    Janson, A. A. M.
    van den Eijnde, R. E. Y.
    Bijl, S.
    Zonneveld-Mulder, M. H. C.
    de Visser, P. C.
    van Deutekom, J. C. T.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 803 - 804
  • [5] Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy
    Assefa, Milyard
    Gepfert, Addison
    Zaheer, Meesam
    Hum, Julia M.
    Skinner, Brian W.
    BIOMEDICINES, 2024, 12 (04)
  • [6] Exon skipping therapy for Duchenne muscular dystrophy - it takes more than an antisense oligonucleotide
    Aartsma-Rus, Annemieke
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [7] Antisense oligonucleotides as a therapy for Duchenne muscular dystrophy
    Wilton, SD
    FRONTIERS IN HUMAN GENETICS: DISEASES AND TECHNOLOGIES, 2001, : 335 - 346
  • [8] Antisense Oligonucleotide-Induced Multiexon Skipping in Duchenne Muscular Dystrophy
    Popplewell, L. J.
    Dickson, G.
    HUMAN GENE THERAPY, 2010, 21 (04) : 507 - 508
  • [9] Antisense therapy corrects Duchenne muscular dystrophy mutation
    Butcher, J
    LANCET NEUROLOGY, 2003, 2 (08): : 458 - 458
  • [10] A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
    Goemans, Nathalie
    Mercuri, Eugenio
    Belousova, Elena
    Komaki, Hirofumi
    Dubrovsky, Alberto
    McDonald, Craig M.
    Kraus, John E.
    Lourbakos, Afrodite
    Lin, Zhengning
    Campion, Giles
    Wang, Susanne X.
    Campbell, Craig
    NEUROMUSCULAR DISORDERS, 2018, 28 (01) : 4 - 15
12345